perianal fistulas

October 24, 2017October 24, 2017

TiGenix Potential Therapy for Crohn’s-related Perianal Fistulas Gets FDA Approval

News

The U.S. Food and Drug Administration (FDA) has granted TiGenix orphan drug designation for its lead candidate Cx601, which aims to treat perianal fistulas caused by Crohn’s disease in patients who have ... Read more

May 5, 2017May 5, 2017

Most Crohn’s Fistulas Are Still Gone a Year After Cx601 Treatment, Trial Shows

News

TiGenix’s Cx601 was able to resolve a painful Crohn’s disease condition known as complex perianal fistulas for a year, according to a Phase 3 trial. Only a quarter of the patients ... Read more

April 7, 2017May 4, 2017

Perianal Fistulas in Crohn’s Patients Effectively Treated in Long Term with Cx601, Study Finds

News

TiGenix’s lead compound Cx601 is a safe and effective long-term treatment of complex perianal fistulas in Crohn’s disease patients, a clinical trial reports. The positive results come from the 104-week extension ... Read more

March 31, 2017April 5, 2017

Crohn’s Disease ‘Scope Series’: Perianal Abscess

Columns, It Could Be Worse - a column by Mary Horsley

Editor’s note: This is the fourth in a series of columns by Mary Horsley about IBD-related procedures. Part one, part two and part three also are available. Continuing my “Scope Series” theme, this ... Read more

October 25, 2016

Extracellular Vesicles at Core of Project to Treat Perianal Fistulas in Crohn’s Disease

News

Esperite’s R&D Division The Cell Factory is working with the Women’s and Children’s Health Department of the University of Padua and the Padua University Hospital in Italy on a innovative ... Read more

August 5, 2016August 5, 2016

Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients Shows Benefits in Phase 3 Trial

IBD News

The 24-week results of a Phase 3 trial showing the effectiveness of the investigational therapy Cx601 in the treatment of complex perianal fistulas in patients with Crohn’s disease were recently published in The ... Read more

July 14, 2016July 14, 2016

Takeda Acquires Rights to Cx601, Possible Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients

News

Takeda Pharmaceuticals has entered an exclusive licensing agreement with TiGenix to develop and commercialize Cx601 as a treatment for complex perianal fistulas in patients with Crohn’s disease. The agreement applies to Europe, ... Read more

August 25, 2015August 25, 2015

TiGenix Lead Compound Cx601 Efficient in Treating CD Patients’ Perianal Fistulas

Crohn's Disease, News

TiGenix, a leading biopharmaceutical company developing therapeutics based on adult stem cells, recently announced the results of the Phase III ADMIRE-CD clinical trial, testing the company’s lead compound Cx601 on Crohn’s disease ... Read more

November 13, 2014November 13, 2014

TiGenix Completes Phase 3 Cx601 Trial Enrollment in Europe

News

Leading European cell therapy company TiGenix NV has just announced the successful full enrollment of patients for a Phase III clinical trial of Cx601, the company’s pipeline treatment for complex perianal fistulas ... Read more

September 10, 2014September 10, 2014

European Medicines Agency Gives Positive Opinion on TiGenix’s Pediatric Investigation Plan For CD Perianal Fistulas Treatment

Crohn's Disease, News

Biopharmaceutical company TiGenix NV, which is currently developing and commercializing novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells (eASC’s) for inflammatory and autoimmune diseases, announced that it received ... Read more